GMAB - Genmab AS - Stock Price & Dividends
Exchange: USA Stocks • Country: Denmark • Currency: USD • Type: Common Stock • ISIN: US3723032062
Antibodies, Cancer, Therapeutics, Treatment, Diseases, Medicines
Genmab A/S is a biotechnology company that specializes in developing innovative antibody therapeutics for the treatment of cancer and other diseases. With a strong focus on research and development, the company has established itself as a leader in the field of antibody therapeutics.
Genmab's product portfolio includes DARZALEX, a human monoclonal antibody approved for the treatment of patients with multiple myeloma (MM). The company is also developing teprotumumab for the treatment of thyroid eye disease, and Amivantamab for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC).
In addition to these products, Genmab has a robust pipeline of promising candidates, including daratumumab for the treatment of MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; and DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB for treating solid tumors. The company is also developing Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia, as well as HexaBody-CD38 and GEN3017 for treating hematological malignancies.
Genmab has a number of ongoing clinical trials, including Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. The company also has various active pre-clinical programs in development.
Genmab has established several strategic collaborations with leading pharmaceutical and biotechnology companies, including Seagen Inc., argenx, AbbVie, BioNTech, Janssen, and Novo Nordisk A/S. These collaborations enable the company to leverage its expertise in antibody development and accelerate the development of new therapeutic antibodies.
Founded in 1999, Genmab A/S is headquartered in Copenhagen, Denmark, and has established itself as a pioneer in the field of antibody therapeutics. With a strong commitment to innovation and a focus on improving patient outcomes, Genmab is well-positioned to continue making significant contributions to the field of cancer treatment and beyond.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
GMAB Stock Overview
Market Cap in USD | 14,448m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2009-06-01 |
GMAB Stock Ratings
Growth 5y | -13.6 |
Fundamental | 59.1 |
Dividend | |
Rel. Performance vs Sector | -7.02 |
Analysts | 3.67/5 |
Fair Price Momentum | 20.06 USD |
Fair Price DCF | 255.97 USD |
GMAB Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
GMAB Growth Ratios
Growth Correlation 3m | -91.7% |
Growth Correlation 12m | -85.4% |
Growth Correlation 5y | -8.1% |
CAGR 5y | 0.81% |
CAGR/Mean DD 5y | 0.04 |
Sharpe Ratio 12m | -1.04 |
Alpha vs SP500 12m | -56.07 |
Beta vs SP500 5y weekly | 0.75 |
ValueRay RSI | 59.31 |
Volatility GJR Garch 1y | 28.37% |
Price / SMA 50 | -5.37% |
Price / SMA 200 | -15.18% |
Current Volume | 1560.5k |
Average Volume 20d | 1490.4k |
External Links for GMAB Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of November 10, 2024, the stock is trading at USD 23.08 with a total of 1,560,527 shares traded.
Over the past week, the price has changed by +2.30%, over one month by -2.16%, over three months by -14.74% and over the past year by -25.55%.
According to ValueRays Forecast Model, GMAB Genmab AS will be worth about 22.1 in November 2025. The stock is currently trading at 23.08. This means that the stock has a potential downside of -4.42%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 39.4 | 70.7 |
Analysts Target Price | 44.8 | 94.0 |
ValueRay Target Price | 22.1 | -4.42 |